Clinical trials: Non-valvular Atrial Fibrillation (AF)
Atrial Fibrillation, Anticoagulants and Bleeding Disorders
Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy
Up to 5% of Atrial Fibrillation (AF) patients may have or develop contraindications to use oral anticoagulation (OAC). Randomized controlled trial (RCT) data suggest that Left Atrial Appendage Occlusion (LAAO) may provide a…
- Trial name
- COMPARE-LAAO (NCT04676880)
- Testing
- Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)
- Where
- 14 sites in Netherlands
- Volunteers
- 609 people
- Sponsor
- R&D Cardiologie
Atrial Fibrillation
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS) to gain insight into the safety of…
- Trial name
- NCT03247582
- Testing
- Edoxaban
- Where
- 4 sites in Hong Kong
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company
Atrial Fibrillation
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients…
- Trial name
- OPTION (NCT03795298)
- Testing
- WATCHMAN FLX Implant, Market-approved OAC
- Where
- 114 sites in United States, Australia and 8 more
- Volunteers
- 1,600 people
- Sponsor
- Boston Scientific Corporation
Non-valvular Atrial Fibrillation
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
This study is designed to gain real-world clinical data on the peri- and post-procedural usage of anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation (NVAF) undergoing successful…
- Trial name
- ENCOURAGE-AF (NCT04519944)
- Testing
- Edoxaban
- Where
- 66 sites in Germany
- Volunteers
- 666 people
- Sponsor
- Daiichi Sankyo
Persistent or Permanent Non-valvular Atrial Fibrillation
Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.
- Trial name
- NCT00623779
- Testing
- AZD0837, Aspirin
- Where
- 38 sites in Denmark, Norway and 4 more
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in…
- Trial name
- NCT03258645
- Testing
- Dabigatran
- Where
- Sweden
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Health Literacy
Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular AF
The risk of stroke is markedly elevated in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is indicated in individuals with moderate and high risk of stroke to the disadvantage of an increased burden from…
- Trial name
- NCT03061123
- Testing
- Questionnaire
- Where
- 8 sites in Austria
- Volunteers
- 91 people
- Sponsor
- Medical University of Graz
Atrial Fibrillation, Percutaneous Coronary Intervention
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate…
- Trial name
- NCT02164864
- Testing
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin
- Where
- 421 sites in United States, Argentina and 39 more
- Volunteers
- 2,725 people
- Sponsor
- Boehringer Ingelheim
Congestive Heart Failure Chronic, Atrial Fibrillation (Permanent)
Inflammation, Epigenetics in CHF Patients With AF
the goal of this case-control cross-sectional study is assessing in a cohort of patients with CHF and permanent AF The serum levels of some candidate cytokine variables and their relationship with some selected metabolic…
- Trial name
- NCT07152301
- Where
- Italy
- Volunteers
- 164 people
- Sponsor
- University of Palermo
Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
WATCHMAN FLX Pro European Registry
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device.
- Trial name
- NCT07262255
- Testing
- Left atrial appendage closure
- Where
- 20 sites in Denmark, Germany and 4 more
- Volunteers
- 189 people
- Sponsor
- Boston Scientific Corporation
Non Valvular Atrial Fibrillation (nv AF)
Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
The goal of this observational study is to learn about the variability of apixaban blood levels and identify the clinical factors that influence them in Asian patients with atrial fibrillation.
- Trial name
- NCT07747948
- Testing
- Apixaban
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Stroke
WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.
- Trial name
- WAVECREST2 (NCT03302494)
- Testing
- Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
- Where
- 25 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- Coherex Medical
Intracranial Hemorrhages, Atrial Fibrillation (AF)
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
Atrial fibrillation is the most common cardiac arrhythmia. In atrial fibrillation, there is a risk that clots can form in the heart, especially in the left atrium. If these clots come loose, there is a risk of stroke.
- Conditions
- Intracranial Hemorrhages, Atrial Fibrillation (AF), Atrial Flutter
- Trial name
- CLEARANCE (NCT04298723)
- Testing
- Percutaneous closure of the LAA (Watchman / Watchman FLX)
- Where
- 39 sites in Germany, Poland
- Volunteers
- 530 people
- Sponsor
- Jena University Hospital
Atrial Fibrillation, AFib
Stroke Feasibility Study
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage.
- Trial name
- NCT01997905
- Testing
- AtriClip LAA Exclusion Device
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- AtriCure, Inc.
Non-valvular Atrial Fibrillation, Acute Coronary Syndrome
Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI
This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany.
- Conditions
- Non-valvular Atrial Fibrillation, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Antithrombotic Therapy
- Trial name
- RIVA-PCI (NCT03315650)
- Where
- 13 sites in Germany
- Volunteers
- 1,632 people
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Non-valvular Atrial Fibrillation (NVAF), Thromboembolism
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device, Perioperative Bleeding
- Trial name
- STEP-AF (NCT07616414)
- Testing
- Stepwise Anticoagulation Regimen, Standard Anticoagulation Regimen
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Atrial Fibrillation, Non-valvular Atrial Fibrillation
Therapy With New Oral Anticoagulants
The aim of the present registry is to characterize and follow patients prospectively and retrospectively with renal impairment who have been prescribed apixaban for the prevention of stroke in atrial fibrillation, with a…
- Trial name
- NCT02222090
- Where
- Israel
- Volunteers
- 1,500 people
- Sponsor
- Sheba Medical Center
Atrial Fibrillation, Coronary Artery Disease
The Greek AntiPlatElet Atrial Fibrillation Registry.
Approximately 5% to 7% of patients undergoing percutaneous coronary intervention for the treatment of coronary artery disease, require chronic oral anticoagulation on top of aspirin and a P2Y12 receptor antagonist, mainly due to…
- Trial name
- GRAPE-AF (NCT03362788)
- Testing
- VKA, NOAC
- Where
- Greece
- Volunteers
- 654 people
- Sponsor
- Attikon Hospital
Atrial Fibrillation, Antithrombotic Therapy
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
More than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome, Percutaneous Coronary Interventions
- Trial name
- ADONIS-PCI (NCT04695106)
- Testing
- Ticagrelor, Dabigatran Etexilate, Aspirin
- Where
- Poland
- Volunteers
- 1,194 people
- Sponsor
- Medical University of Gdansk
Non-valvular Atrial Fibrillation, Embolic Stroke
Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
This clinical study is a prospective, multi-center, non-interventional study designed to investigate the safety and effectiveness of percutaneous LAA appendage closure by using LAmbre™ Left Atrial Appendage Occluder System.
- Trial name
- NCT04559243
- Testing
- Transthoracic Echocardiography
- Where
- 5 sites in China
- Volunteers
- 579 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.